TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.78% | 42.97% | 57.68% | 49.39% | -20.12% |
| Total Depreciation and Amortization | -6.98% | -0.97% | 9.78% | 8.77% | 70.87% |
| Total Amortization of Deferred Charges | 117.74% | 213.48% | -- | -- | -- |
| Total Other Non-Cash Items | -15.76% | -39.36% | -111.57% | -134.44% | 514.78% |
| Change in Net Operating Assets | 150.14% | 67.41% | -1,113.16% | -1,878.21% | -25,570.83% |
| Cash from Operations | 52.08% | 48.53% | 32.32% | 19.25% | 10.86% |
| Capital Expenditure | -38.98% | -30.18% | -59.66% | 41.33% | -58.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 1,570.59% |
| Cash from Investing | -26.99% | 47.83% | 37.15% | 78.27% | 55.17% |
| Total Debt Issued | -60.00% | -60.00% | -- | -- | -- |
| Total Debt Repaid | -11.49% | -29.89% | -52.87% | 3.45% | 54.69% |
| Issuance of Common Stock | 102.18% | 357.25% | 288.89% | 8,622.35% | 10,930.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.82% | -106.25% | -108.72% | -107.26% | -107.31% |
| Cash from Financing | -4.30% | -43.50% | -10.69% | -30.56% | -42.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 214.05% | -21.05% | 434.82% | -232.03% | -207.53% |